Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm

QR Code

Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm

Giancarlo Cerveri,1 Camilla Gesi,2 Claudio Mencacci21Mental Health Department, ASST Lodi, Lodi, Italy; 2Mental Health Department, ASST Fatebenefratelli-Sacco, Milan, ItalyAbstract: The clinical presentation of schizophrenia encompasses symptoms divided into three dimensions: positive, negative, and...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Cerveri G, Gesi C, Mencacci C
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	cariprazine mental disorders symptoms Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/f45819950f414a61b3579ec92f15b2c7
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
par: Aleksandr M. Reznik, et autres
Publié: (2020)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
par: Octavian Vasiliu
Publié: (2021)

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
par: Montes JM, et autres
Publié: (2021)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
par: Aubel T
Publié: (2021)

Update on schizophrenia and bipolar disorder: focus on cariprazine
par: Roberts RJ, et autres
Publié: (2016)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
par: Borjanka Batinic, et autres
Publié: (2021)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
par: Citrome L
Publié: (2018)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
par: Liang Y, et autres
Publié: (2017)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
par: Correll CU, et autres
Publié: (2020)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
par: Correll CU, et autres
Publié: (2019)

Update on the management of symptoms in schizophrenia: focus on amisulpride
par: Ann M Mortimer
Publié: (2009)

Association Between Autistic Symptoms and Self-Stigma in Patients with Schizophrenia Spectrum Disorders
par: Komatsu H, et autres
Publié: (2020)

Measuring negative symptoms in patients with schizophrenia: reliability and validity of the Korean version of the Motivation and Pleasure Scale-Self-Report
par: Kim JS, et autres
Publié: (2016)

Influence of CFH gene on symptom severity of schizophrenia
par: Zhang C, et autres
Publié: (2017)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
par: Barabássy Á, et autres
Publié: (2021)

Cognitive dysfunction and negative symptoms in patients with schizophrenia and their first-degree relatives from simplex and multiplex families
par: Zhang Z, et autres
Publié: (2018)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
par: Barabássy Á, et autres
Publié: (2021)

Validation of the Chinese Version of the 16-Item Negative Symptom Assessment
par: Huang B, et autres
Publié: (2020)

Metacognitive Beliefs, Cognitive Functioning, Psychiatric Symptoms and Empathy in People with Schizophrenia
par: Chuang SP, et autres
Publié: (2021)

Validation of the Dutch Version of the Brief Negative Symptom Scale
par: Seelen-de Lang BL, et autres
Publié: (2020)

New drugs in psychiatry - cariprazine, lurasidone, esketamine
par: Pożarowska Kinga, et autres
Publié: (2021)

Residual symptoms in patients with partial versus complete remission of a major depressive disorder episode: patterns of painful physical symptoms in depression
par: Harada E, et autres
Publié: (2016)

Associations between the mismatch-negativity component and symptom severity in children and adolescents with attention deficit/hyperactivity disorder
par: Yamamuro K, et autres
Publié: (2016)

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia
par: Sicras-Mainar A, et autres
Publié: (2014)

Pilot Validation Study of the Japanese Translation of the Brief Negative Symptoms Scale (BNSS)
par: Hashimoto N, et autres
Publié: (2019)

Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms
par: Urban-Kowalczyk M, et autres
Publié: (2015)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
par: Ibrahim Turkoz, et autres
Publié: (2008)

Dementia-related neuropsychiatric symptoms: inequalities in pharmacological treatment and institutionalization
par: Mar J, et autres
Publié: (2019)

Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial
par: Zhuo K, et autres
Publié: (2019)

Rumination, posttraumatic stress disorder, and mood symptoms in borderline personality disorder
par: Dell'Osso L, et autres
Publié: (2019)

Cognitive behavioral therapy for somatic symptom disorders in later life: a prospective comparative explorative pilot study in two clinical populations
par: Verdurmen MJH, et autres
Publié: (2017)

Suicidality and symptoms of anxiety, irritability, and agitation in patients experiencing manic episodes with depressive symptoms: a naturalistic study
par: Eberhard J, et autres
Publié: (2016)

Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
par: Weng JJ, et autres
Publié: (2019)

The prognosis and changes of regional brain gray matter volume in MDD with gastrointestinal symptoms
par: Liu P, et autres
Publié: (2019)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
par: Gopal S, et autres
Publié: (2020)

Gray Matter Density of the Dorsomedial Prefrontal Cortex Mediates the Relationship Between Catastrophizing and Anxiety in Somatic Symptom Disorder
par: Pan X, et autres
Publié: (2021)

The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms
par: Sugawara N, et autres
Publié: (2020)

Mental health care use in medically unexplained and explained physical symptoms: findings from a general population study
par: van Eck van der Sluijs JF, et autres
Publié: (2016)

Combined Effects of Mother’s, Father’s and Teacher’s Psychological Distress on Schoolchildren’s Mental Health Symptoms
par: Li S, et autres
Publié: (2021)

Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development
par: Gregory P. Strauss, et autres
Publié: (2021)